T-Cadherin Modulates Tumor-Associated Molecules in Gallbladder Cancer Cells

REFERENCES

• Lee, S.W. H-cadherin, a novel cadherin with growth inhibitory functions and diminished expression in human breast cancer. Nat Med 1996, 2, 776–782.
   PubMed Web of Science ®Google Scholar
• Sato, M.; Mori, Y.; Sakurada, A.; Fujimura, S.; Horii, A. The H-cadherin (CDH13) gene is inactivated in human lung cancer. Hum Genet 1998, 103, 96–101. [Published erratum in Hum Genet 1998, 103, 532].
   Google Scholar
• Toyooka, K.O.; Toyooka, S.; Virmani, A.K.; Sathyanarayana, U.G.; Euhus, D.M.; Gilcrease, M.; Minna, J.D.; Gazdar, A.F. Loss of expression and aberrant methylation of the CDH13 (H-Cadherin) gene in breast and lung carcinomas. Cancer Res 2001, 61, 4556–4560.
   PubMed Web of Science ®Google Scholar
• Toyooka, S.; Toyooka, K.O.; Harada, K.; Miyajima, K.; Makarla, P.; Sathyanarayana, U.G.; Yin, J.; Sato, F.; Shivapurkar, N.; Meltzer, S.; Gazdar, A.F. Aberrant methylation of the CDH13 (H-cadherin) promoter region in colorectal cancers and adenomas. Cancer Res 2002, 62, 3382–3386.
   PubMed Web of Science ®Google Scholar
• Takeuchi, T.; Liang, S.B.; Matsuyoshi, N.; Zhou, S.; Miyachi, Y.; Sonobe, H.; Ohtsuki, Y. Loss of T-cadherin (CDH13, H-cadherin) expression in cutaneous squamous cell carcinoma. Lab Invest 2002, 82, 1023–1029.
   PubMed Web of Science ®Google Scholar
• Takeuchi, T.; Liang, S.B.; Ohtsuki, Y. Down-regulation of expression of a novel cadherin molecule, T-cadherin, in basal cell carcinoma of the skin. Mol Carcinog 2002, 35, 173–179.
   PubMed Web of Science ®Google Scholar
• Sakai, M.; Hibi, K.; Koshikawa, K.; Inoue, S.; Takeda, S.; Kaneko, T.; Nakao, A. Frequent promoter methylation and gene silencing of CDH13 in pancreatic cancer. Cancer Sci 2004, 95, 588–591.
   PubMed Web of Science ®Google Scholar
• Lee, S.W.; Reimer, C.L.; Campbell, D.B.; Cheresh, P.; Duda, R.B.; Kocher, O. H-cadherin expression inhibits in vitro invasiveness and tumor formation in vivo. Carcinogenesis 1998, 19, 1157–1159.
   PubMed Web of Science ®Google Scholar
• Ranscht, B.; Dours-Zimmermann, M.T. T-cadherin, a novel cadherin cell adhesion molecule in the nervous system, lacks the conserved cytoplasmic region. Neuron 1991, 7, 391–402.
   PubMed Web of Science ®Google Scholar
• Nagafuchi, A.; Takeichi, M. Cell binding function of E-cadherin is regulated by the cytoplasmic domain. EMBO J 1988, 7, 3679–3684.
   PubMed Web of Science ®Google Scholar
• Dames, S.A.; Bang, E.; Haüssinger, D.; Ahrens, T.; Engel, J.; Grzesiek, S. Insights into the low adhesive capacity of human T-cadherin from the NMR structure of its N-terminal extracellular domain. J Biol Chem 2008, 283, 23485–23495.
   PubMedGoogle Scholar
• Takeuchi, T.; Misaki, A.; Liang, S.B.; Tachibana, A.; Hayashi, N.; Sonobe, H.; Ohtsuki, Y. Expression of T-cadherin (CDH13, H-cadherin) in human brain and its characteristics as a negative growth regulator of EGF in neuroblastoma cells. J Neurochem 2000, 74, 1489–1497.
   PubMed Web of Science ®Google Scholar
• Li, X.; Massa, P.E.; Hanidu, A.; Peet, G.W.; Aro, P.; Savitt, A.; Mische, S.; Li, J.; Marcu, K.B. IKKalpha, IKKbeta, and NEMO/IKKgamma are each required for the NF-kappa B-mediated inflammatory response program. J Biol Chem 2002, 277, 45129–45140.
   PubMed Web of Science ®Google Scholar
• Huang, Z.Y.; Wu, Y.; Hedrick, N.; Gutmann, D.H. T-cadherin-mediated cell growth regulation involves G2 phase arrest and requires p21(CIP1/WAF1) expression. Mol Cell Biol 2003, 23, 566–578.
   PubMed Web of Science ®Google Scholar
• Ivanov, D.; Philippova, M.; Allenspach, R.; Erne, P.; Resink, T. T-cadherin upregulation correlates with cell-cycle progression and promotes proliferation of vascular cells. Cardiovasc Res 2004, 64, 132–143.
   PubMed Web of Science ®Google Scholar
• Gourgiotis, S.; Kocher, H.M.; Solaini, L.; Yarollahi, A.; Tsiambas, E.; Salemis, N.S. Gallbladder cancer. Am J Surg 2008, 196, 252–264.
   PubMed Web of Science ®Google Scholar
• Adachi, Y.; Takeuchi, T.; Nagayama, T.; Ohtsuki, Y.; Furihata, M. Zeb1-mediated T-cadherin repression increases the invasive potential of gallbladder cancer. FEBS Lett 2009, 583, 430–436.
   Google Scholar
• Horiuchi, H.; Kawamata, H.; Fujimori, T.; Kuroda, Y. A MEK inhibitor (U0126) prolongs survival in nude mice bearing human gallbladder cancer cells with K-ras mutation: analysis in a novel orthotopic inoculation model. Int J Oncol 2003, 23, 957–963.
   PubMed Web of Science ®Google Scholar
• Tekant, Y.; Davydova, J.; Ramirez, P.J.; Curiel, D.T.; Vickers, S.M.; Yamamoto, M. Oncolytic adenoviral therapy in gallbladder carcinoma. Surgery 2005, 137, 527–535.
   PubMed Web of Science ®Google Scholar
• Towbin, H.; Staehelin, T.; Gordon, J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979, 76, 4350–4354.
   PubMed Web of Science ®Google Scholar
• Takeuchi, T.; Kuro-o, M.; Miyazawa, H.; Ohtsuki, Y.; Yamamoto, H. Transgenic expression of a novel thymic epithelial cell antigen stimulates abberant development of thymocytes. J Immunol 1997, 159, 726–733.
   PubMed Web of Science ®Google Scholar
• Tanno, S.; Yanagawa, N.; Habiro, A.; Koizumi, K.; Nakano, Y.; Osanai, M.; Mizukami, Y.; Okumura, T.; Testa, J.R.; Kohgo, Y. Serine/threonine kinase AKT is frequently activated in human bile duct cancer and is associated with increased radioresistance. Cancer Res 2004, 64, 3486–3490.
   PubMed Web of Science ®Google Scholar
• Alessi, D.R.; Andjelkovic, M.; Caudwell, B.; Cron, P.; Morrice, N.; Cohen, P.; Hemmings, B.A. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO Journal 1996, 15, 6541–6551.
   PubMed Web of Science ®Google Scholar
• Chuikov, S.; Kurash, J.K.; Wilson, J.R.; Xian, B.; Justin, N.; Ivanov, G.S.; McKinney, K.; Tempst, P.; Prives, C.; Gamblin, S.J.; Barlev, N.A.; Reinberg, D. Regulation of p53 activity through lysine methylation. Nature 2004, 432, 353–360.
   PubMed Web of Science ®Google Scholar
• Takagi, S.; Naito, E.; Yamanouchi, H.; Ohtsuka, H.; Kominami, R.; Yamamoto, M. Mutation of the p53 gene in gallbladder cancer. Tohoku J Exp Med 1994, 172, 283–289.
   PubMed Web of Science ®Google Scholar
• Wee, A.; Teh, M.; Raju, G.C. Clinical importance of p53 protein in gallbladder carcinoma and its precursor lesions. J Clin Pathol 1994, 47, 453–456.
   PubMed Web of Science ®Google Scholar
• Diamantis, I.; Karamitopoulou, E.; Perentes, E.; Zimmermann, A. p53 protein immunoreactivity in extrahepatic bile duct and gallbladder cancer: correlation with tumor grade and survival. Hepatology 1995, 22, 774–779.
   PubMed Web of Science ®Google Scholar
• Datta, S.R.; Brunet, A.; Greenberg, M.E. Cellular survival: a play in three akts. Gene Dev 1999, 13, 2905–2927.
   PubMed Web of Science ®Google Scholar
• Bae, S.S.; Cho, H.; Mu, J.; Birnbaum, M.J. Isoform-specific regulation of insulin-dependent glucose uptake by Akt/protein kinase B. J Biol Chem 2003, 278, 49530–49536.
   PubMed Web of Science ®Google Scholar
• Nakatani, K.; Thompson, D.A.; Barthel, A.; Sakaue, H.; Liu, W.; Weigel, R.J.; Roth, R.A. Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem 1999, 274, 21528–21532.
   PubMed Web of Science ®Google Scholar
• Stahl, J.M.; Sharma, A.; Cheung, M.; Zimmerman, M.; Cheng, J.Q.; Bosenberg, M.W.; Kester, M.; Sandirasegarane, L.; Robertson, G.P. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res 2004, 64, 7002–7010.
   PubMed Web of Science ®Google Scholar
• Cristiano, B.E.; Chan, J.C.; Hannan, K.M.; Lundie, N.A.; Marmy-Conus, N.J.; Campbell, I.G.; Phillips, W.A.; Robbie, M.; Hannan, R.D.; Pearson, R.B. A specific role for AKT3 in the genesis of ovarian cancer through modulation of G(2)-M phase transition. Cancer Res 2006, 66, 11718–11725.
   PubMed Web of Science ®Google Scholar
• Jacinto, E.; Loewith, R.; Schmidt, A.; Lin, S.; Ruegg, M.A.; Hall, A.; Hall, M.N. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004, 6, 1122–1128.
   PubMed Web of Science ®Google Scholar
• Jang, I.K.; Hu, R.; Lacana, E.; D'Adamio, L.; Gu, H. Apoptosis-linked gene 2-deficient mice exhibit normal T-cell development and function. Mol Cell Biol 2002, 22, 4094–4100.
   PubMed Web of Science ®Google Scholar
• Krebs, J.; Saremaslani, P.; Caduff, R. ALG-2: a Ca2+-binding modulator protein involved in cell proliferation and in cell death. Biochim Biophys Acta 2002, 1600, 68–73.
   PubMed Web of Science ®Google Scholar
• la Cour, J.M.; Mollerup, J.; Winding, P.; Tarabykina, S.; Sehested, M.; Berchtold, M.W. Up-regulation of ALG-2 in hepatomas and lung cancer tissue. Am J Pathol 2003, 163, 81–89.
   PubMed Web of Science ®Google Scholar
• Aviel-Ronen, S.; Coe, B.P.; Lau, S.K.; da Cunha Santos, G.; Zhu, C.Q.; Strumpf, D.; Jurisica, I.; Lam, W.L.; Tsao, M.S. Genomic markers for malignant progression in pulmonary adenocarcinoma with bronchioloalveolar features. Proc Natl Acad Sci USA 2008, 105, 10155–10160.
   PubMed Web of Science ®Google Scholar
• Tsuchiya, N.; Ochiai, M.; Nakashima, K.; Ubagai, T.; Sugimura, T.; Nakagama, H. SND1, a component of RNA-induced silencing complex, is up-regulated in human colon cancers and implicated in early stage colon carcinogenesis. Cancer Res 2007, 67, 9568–9576.
   PubMed Web of Science ®Google Scholar